Tempest Therapeutics, Inc.
TPST · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | -0.25 | 4.67 |
| FCF Yield | 31.07% | -24.38% | -3.35% | -2.17% |
| EV / EBITDA | -2.54 | -2.31 | -21.29 | -45.94 |
| Quality | ||||
| ROIC | -43.19% | -45.12% | -40.35% | -36.14% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.93 | 1.07 | 0.74 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 200.00% | 20.84% | 0.44% | -77.06% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.79 | 1.10 | 0.43 |
| Interest Coverage | -173.17 | -67.93 | -56.35 | -32.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,334.93 | -2,894.56 | -907.41 | -1,558.47 |